Loss of function of the tumour suppressor PTEN, which results in activation of the PI3K/AKT pathway, occurs in 10–30% of melanomas, frequently concurrent with activating BRAF mutations (Tsao et al, 1998; Zhou et al, 2000; Haluska et al, 2006). This evidence concerns the gene AKT1 and melanoma.